Bicycle Begin Period Cash Flow from 2010 to 2025
| BCYC Stock | USD 13.14 0.37 2.90% |
Begin Period Cash Flow | First Reported 2018-03-31 | Previous Quarter 457 M | Current Value 961.4 M | Quarterly Volatility 214.3 M |
Check Bicycle Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicycle Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 1.4 M, Interest Income of 16.9 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 40.62, Dividend Yield of 0.0 or PTB Ratio of 1.9. Bicycle financial statements analysis is a perfect complement when working with Bicycle Therapeutics Valuation or Volatility modules.
Bicycle | Begin Period Cash Flow |
Latest Bicycle Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Bicycle Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Bicycle Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicycle Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Bicycle Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 125,734,722 | |
| Geometric Mean | 41,518,317 | |
| Coefficient Of Variation | 131.59 | |
| Mean Deviation | 135,588,243 | |
| Median | 63,380,000 | |
| Standard Deviation | 165,455,745 | |
| Sample Variance | 27375.6T | |
| Range | 429.3M | |
| R-Value | 0.84 | |
| Mean Square Error | 8405.1T | |
| R-Squared | 0.71 | |
| Significance | 0.000038 | |
| Slope | 29,353,946 | |
| Total Sum of Squares | 410634.1T |
Bicycle Begin Period Cash Flow History
About Bicycle Therapeutics Financial Statements
Bicycle Therapeutics stakeholders use historical fundamental indicators, such as Bicycle Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Bicycle Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bicycle Therapeutics' assets and liabilities are reflected in the revenues and expenses on Bicycle Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bicycle Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 390 M | 409.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:Check out the analysis of Bicycle Therapeutics Correlation against competitors. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.28) | Revenue Per Share | Quarterly Revenue Growth (0.50) | Return On Assets | Return On Equity |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.